Dashboard
Poor Management Efficiency with a low ROCE of 1.31%
- The company has been able to generate a Return on Capital Employed (avg) of 1.31% signifying low profitability per unit of total capital (equity and debt)
Poor long term growth as Net Sales has grown by an annual rate of 73.79% and Operating profit at 4.11% over the last 5 years
The company has declared Negative results for the last 3 consecutive quarters
Risky -
Stock DNA
Pharmaceuticals & Biotechnology
CNY 11,875 Million (Large Cap)
NA (Loss Making)
NA
0.00%
0.54
-68.60%
20.36
Total Returns (Price + Dividend) 
Bio-Thera Solutions, Ltd. for the last several years.
Risk Adjusted Returns v/s 
News

Bio-Thera Solutions Hits Day Low of CNY 26.32 Amid Price Pressure
Bio-Thera Solutions, a significant player in the Pharmaceuticals & Biotechnology sector, faced a challenging trading day on October 14, 2025, with a notable decline. The company has struggled with consistent growth, reporting negative results for three consecutive quarters and a low Return on Capital Employed, raising concerns about its financial health.
Read More
Bio-Thera Solutions Hits Day Low of CNY 26.70 Amid Price Pressure
Bio-Thera Solutions faced a decline on October 13, 2025, contrasting with the broader market. The company has seen a significant drop in stock performance over the past week and month, alongside ongoing challenges such as low management efficiency and liquidity concerns, despite a positive annual return.
Read More Announcements 
Corporate Actions 
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot
Shareholding Compare (%holding) 
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ
QoQ Growth in quarter ended Jun 2025 is 13.65% vs 27.79% in Mar 2025
QoQ Growth in quarter ended Jun 2025 is 66.13% vs 35.66% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'24
YoY Growth in year ended Dec 2024 is 5.46% vs 54.91% in Dec 2023
YoY Growth in year ended Dec 2024 is -29.35% vs 17.88% in Dec 2023






